Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
10 Mar 2017
The addition of pravastatin to standard chemotherapy does not improve outcomes in patients with small-cell lung cancer (SCLC), results of a study have shown.
Tristan Manalac, 03 Dec 2019
Incorporating basic tumour characteristics, such as hormone receptor status and tumour origin, improves the power of the cell-loss metric to predict response to treatment, according to a new study presented at the recently concluded 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Audrey Abella, 3 days ago
A moderately hypofractionated radiotherapy (RT) dose schedule was noninferior to conventional RT, according to the 8-year outcomes from the CHHiP* trial presented at ASCO GU 2020.

Alternative sunitinib dosing regimens prolong survival in metastatic renal cell carcinoma

12 Feb 2020

Alternative dosing regimens of sunitinib appear to be effective in improving survival outcomes of patients with metastatic renal cell carcinoma (MRCC), results of a study have shown.

“Standard dosing regimen of sunitinib for MRCC consists of 4 weeks treatment followed by 2 weeks rest (intermittent dosing),” the authors said. “Alternative regimens have been suggested, including continuous daily dosing and nonconventional dosing (eg, 2 weeks on/1 week off), to provide more individualized therapy with less toxicities.”

The study included 180 patients, most of which received intermittent dosing (n=120; 67 percent), followed by continuous dosing (n=32; 18 percent) and nonconventional dosing (n=28; 16 percent).

Continuous dosing, compared to intermittent dosing, was associated with comparable overall survival (median, 1 vs 13 months; hazard ratio [HR], 0.67; 95 percent confidence interval [CI], 0.43–1.06; p=0.088). On the other hand, nonconventional dosing correlated with significantly longer overall survival (median, 9 vs 23 months; HR, 0.55, 95 percent CI, 0.34–0.90; p=0.016).

Likewise, progression-free survival was significantly better for continuous dosing (median, 4 vs 9 months; HR, 0.61, 95 percent CI, 0.40–0.94; p=0.025) and for nonconventional dosing (median, 4 vs 10 months; HR, 0.61, 95 percent CI, 0.39–0.95; p=0.03) compared to intermittent dosing.

One in five patients discontinued sunitinib treatment due to adverse events. This finding was consistent with previous sunitinib trials.

In this study, MRCC patients treated with sunitinib between 1 July 2017 and 1 July 2011 were included. The authors retrospectively reviewed medical records and dispensing data to categorize sunitinib dosing as intermittent, continuous or nonconventional.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
10 Mar 2017
The addition of pravastatin to standard chemotherapy does not improve outcomes in patients with small-cell lung cancer (SCLC), results of a study have shown.
Tristan Manalac, 03 Dec 2019
Incorporating basic tumour characteristics, such as hormone receptor status and tumour origin, improves the power of the cell-loss metric to predict response to treatment, according to a new study presented at the recently concluded 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Audrey Abella, 3 days ago
A moderately hypofractionated radiotherapy (RT) dose schedule was noninferior to conventional RT, according to the 8-year outcomes from the CHHiP* trial presented at ASCO GU 2020.